Reproductive disordersReproductive disorders, particularly those involving diminished ovarian functionOvarian function due to pathogenic conditions or agingAging, are among the most challenging to treat. Primary treatment includes hormone replacement therapyHormone replacement therapy using exogenous sex hormonesSex hormones to minder menopausal syndromesMenopausal syndromes and prevent long-term issues such as osteoporosisOsteoporosis. However, this approach fails to improve ovarian functionsOvarian function and increases the risk of cardiovascular diseasesCardiovascular diseases and cancerCancer. Recent advancements in cell therapyCell therapy and regenerative medicineRegenerative medicine have introduced new applications for treating reproductive disorders. This review explores the potential of stem cellsStem cells in managing ovarian deficiencyOvarian deficiency and female sexual dysfunctionFemale sexual dysfunction. Studies on pluripotentStem cellspluripotent female germline stem cellsFemale germline stem cells and induced pluripotentStem cellspluripotent stem cellsInduced pluripotent stem cellsiPSCsInduced pluripotent stem cells (iPSCs) are still in the exploratory stage. Therapies using multipotentStem cellsmultipotent mesenchymal stem cellsMesenchymal stem cells (MSCsMSCsMesenchymal stem cells) are the most advanced in clinical translation. MSCs have been derived from both adult and neonatal sources, including adipose tissueMesenchymal stem cellsfrom adipose tissue, bone marrowMesenchymal stem cellsfrom bone marrow, menstrual bloodMesenchymal stem cellsfrom menstrual blood, umbilical cordMesenchymal stem cellsfrom umbilical cord, and amniotic membraneMesenchymal stem cellsfrom amniotic membrane. A few studies have also been conducted with autologousCell therapyautologous bone marrowMesenchymal stem cellsfrom bone marrow-derived mononuclear cellsBone marrow-derived mononuclear cells (BM-MNCsBM-MNCsBone marrow-derived mononuclear cells) and mobilized peripheral bloodMobilized peripheral blood. Overall, clinical trials have demonstrated the safetySafety and promising outcome of these approaches, with some patients achieving successful pregnanciesEfficacysuccessful pregnancies. However, randomized controlled studies with larger patient number are crucial toCell therapy optimizeStem cells cellStem cellspluripotent therapyCell therapy protocols and ensure long-term safetySafety and effectiveness inMenopausal syndromessexual dysfunction treating reproductive disorders.

Cell Therapy for Ovarian Deficiency and Female Sexual Dysfunction

章节
发表日期：

2025年

查看全文

Van T. Hoang,
Nguyen Thi Tan Sinh

摘要

Reproductive disordersReproductive disorders, particularly those involving diminished ovarian functionOvarian function due to pathogenic conditions or agingAging, are among the most challenging to treat. Primary treatment includes hormone replacement therapyHormone replacement therapy using exogenous sex hormonesSex hormones to minder menopausal syndromesMenopausal syndromes and prevent long-term issues such as osteoporosisOsteoporosis. However, this approach fails to improve ovarian functionsOvarian function and increases the risk of cardiovascular diseasesCardiovascular diseases and cancerCancer. Recent advancements in cell therapyCell therapy and regenerative medicineRegenerative medicine have introduced new applications for treating reproductive disorders. This review explores the potential of stem cellsStem cells in managing ovarian deficiencyOvarian deficiency and female sexual dysfunctionFemale sexual dysfunction. Studies on pluripotentStem cellspluripotent female germline stem cellsFemale germline stem cells and induced pluripotentStem cellspluripotent stem cellsInduced pluripotent stem cellsiPSCsInduced pluripotent stem cells (iPSCs) are still in the exploratory stage. Therapies using multipotentStem cellsmultipotent mesenchymal stem cellsMesenchymal stem cells (MSCsMSCsMesenchymal stem cells) are the most advanced in clinical translation. MSCs have been derived from both adult and neonatal sources, including adipose tissueMesenchymal stem cellsfrom adipose tissue, bone marrowMesenchymal stem cellsfrom bone marrow, menstrual bloodMesenchymal stem cellsfrom menstrual blood, umbilical cordMesenchymal stem cellsfrom umbilical cord, and amniotic membraneMesenchymal stem cellsfrom amniotic membrane. A few studies have also been conducted with autologousCell therapyautologous bone marrowMesenchymal stem cellsfrom bone marrow-derived mononuclear cellsBone marrow-derived mononuclear cells (BM-MNCsBM-MNCsBone marrow-derived mononuclear cells) and mobilized peripheral bloodMobilized peripheral blood. Overall, clinical trials have demonstrated the safetySafety and promising outcome of these approaches, with some patients achieving successful pregnanciesEfficacysuccessful pregnancies. However, randomized controlled studies with larger patient number are crucial toCell therapy optimizeStem cells cellStem cellspluripotent therapyCell therapy protocols and ensure long-term safetySafety and effectiveness inMenopausal syndromessexual dysfunction treating reproductive disorders.